Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
about
Inferences of drug responses in cancer cells from cancer genomic features and compound chemical and therapeutic propertiesElevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic CancerRenal function during rofecoxib therapy in patients with metastatic cancer: retrospective analysis of a prospective phase II trial.Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report.Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.The molecular targets for the diagnosis and treatment of pancreatic cancer.Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress.Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant PathwaySp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma.Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer.Jekyll and Hyde: the role of the microenvironment on the progression of cancer.Influence of the tumor microenvironment on angiogenesis.Brief overview of selected approaches in targeting pancreatic adenocarcinoma.Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ω-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs.The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models.The 'N-factors' in pancreatic cancer: functional relevance of NF-κB, NFAT and Nrf2 in pancreatic cancer.Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity.Arousal of cancer-associated stromal fibroblasts: palladin-activated fibroblasts promote tumor invasion.Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor.Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancreatic carcinoma: a phase I/II trial.Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update.Cyclooxygenase 2 promoted the tumorigenecity of pancreatic cancer cells.Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy.Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers
P2860
Q28829729-51D523F4-9A60-4760-8426-BDA8B8F8D7C7Q33670223-C124ACE1-7559-40F5-A561-E5EB460BD728Q33786234-91BFC13B-BD0B-4D09-9140-18686C538763Q34067846-70A30A70-344F-4B65-BF31-CCB4198080B3Q34142424-01C45CD5-51BE-4E37-9D09-BD6E29AD00FDQ34290118-98F3C7FD-9E85-496A-99D8-E97DD3B3B91FQ34494019-83D13F6B-AE10-4F9F-8BF1-556CF3A59D2DQ34665177-0063247D-19BB-4629-A66A-F49805FD2B5FQ35222202-FB9BA8BB-6F15-4900-B8D4-AFF216971855Q36218965-124C68F3-2301-4D94-960D-A43582D529FFQ37317518-7061F255-34E5-4D80-A302-7D65399D1A10Q37617965-04D950AC-34F4-46AD-8A95-7D24FF6E906AQ37815128-419BC3A2-32C5-4FB5-BC41-6C144EDD8E00Q37854731-E53FE6CF-140B-407A-A2B6-0985D5BA50C0Q38199723-72B25F12-8199-4BC7-B1C6-1B3FE766E12AQ38694488-9FC07740-F62C-48E5-9345-B4E29B35D63EQ38760434-D166D5F4-C1A6-4217-883A-BD7F1FBF5C99Q39462851-2C428133-1558-4E41-89B6-033D91D560CFQ39670791-46129D0B-9CC0-49C2-B0AC-F7839A2E711AQ39834032-E85348E2-A4CA-4230-AEF9-2D0E51EEC56EQ42194464-190927E1-A931-480D-8281-69F203DB4D52Q43198689-DE9AE10E-5975-4CBB-901C-4EA0DA152A07Q49766057-94048BD9-5ACB-4C53-8975-14EF9AD8D3ADQ51604439-34A11EE5-CB26-4D47-9802-E88BF0A4C164Q53247594-B84A720B-EFA7-4E52-BF3A-F393E2477232Q54609676-C36913AA-8694-4521-9131-215FEF336E01Q56775849-CA83086C-BC60-4671-BDB7-A3A3D5A9E3C4
P2860
Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase II trial of gemcitabine, ...... th advanced pancreatic cancer.
@ast
Phase II trial of gemcitabine, ...... th advanced pancreatic cancer.
@en
type
label
Phase II trial of gemcitabine, ...... th advanced pancreatic cancer.
@ast
Phase II trial of gemcitabine, ...... th advanced pancreatic cancer.
@en
prefLabel
Phase II trial of gemcitabine, ...... th advanced pancreatic cancer.
@ast
Phase II trial of gemcitabine, ...... th advanced pancreatic cancer.
@en
P2093
P1476
Phase II trial of gemcitabine, ...... th advanced pancreatic cancer.
@en
P2093
Allan Lipton
Cynthia Campbell-Baird
Harold Harvey
Lois Witters
Suhail Ali
P304
P356
10.1097/MCG.0B013E3181CDA097
P577
2010-04-01T00:00:00Z